Table 2.

Summary of TSS for pretreatment expression of HR23B in phase II trial CTCL biopsies

TSS	PR/SD	PD	Total
≥6	11	5	16
<6	2	3	5
Total	13	8	21

Distribution of patients categorized as having high (≥6) or low (<6) TSS for HR23B according to response to treatment (PR/SD) or no response to treatment (PD) in patients from the phase II trial. Values relating to the pretreatment expression of HR23B are shown. Statistical significance was assessed using Fisher's exact test. Positive predictive value: 68.8%; one-tailed P = 0.262126; two-tailed P = 0.325372.